These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease. Perla FM; Prelati M; Lavorato M; Visicchio D; Anania C Children (Basel); 2017 Jun; 4(6):. PubMed ID: 28587303 [TBL] [Abstract][Full Text] [Related]
25. Liver transplantation and non-alcoholic fatty liver disease. Zezos P; Renner EL World J Gastroenterol; 2014 Nov; 20(42):15532-8. PubMed ID: 25400437 [TBL] [Abstract][Full Text] [Related]
26. Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets. Tanase DM; Gosav EM; Petrov D; Jucan AE; Lacatusu CM; Floria M; Tarniceriu CC; Costea CF; Ciocoiu M; Rezus C Diagnostics (Basel); 2021 Nov; 11(11):. PubMed ID: 34829402 [TBL] [Abstract][Full Text] [Related]
27. Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis. Martínez L; Torres S; Baulies A; Alarcón-Vila C; Elena M; Fabriàs G; Casas J; Caballeria J; Fernandez-Checa JC; García-Ruiz C Oncotarget; 2015 Dec; 6(39):41479-96. PubMed ID: 26539645 [TBL] [Abstract][Full Text] [Related]
28. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease. Li X; Wang Z; Klaunig JE Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929 [TBL] [Abstract][Full Text] [Related]
29. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499 [TBL] [Abstract][Full Text] [Related]
31. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Arguello G; Balboa E; Arrese M; Zanlungo S Biochim Biophys Acta; 2015 Sep; 1852(9):1765-78. PubMed ID: 26027904 [TBL] [Abstract][Full Text] [Related]
32. Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis. Schröder T; Kucharczyk D; Bär F; Pagel R; Derer S; Jendrek ST; Sünderhauf A; Brethack AK; Hirose M; Möller S; Künstner A; Bischof J; Weyers I; Heeren J; Koczan D; Schmid SM; Divanovic S; Giles DA; Adamski J; Fellermann K; Lehnert H; Köhl J; Ibrahim S; Sina C Mol Metab; 2016 Apr; 5(4):283-295. PubMed ID: 27069868 [TBL] [Abstract][Full Text] [Related]
33. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Vernon G; Baranova A; Younossi ZM Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852 [TBL] [Abstract][Full Text] [Related]
34. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. Liu J; Xu Y; Hu Y; Wang G Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477 [TBL] [Abstract][Full Text] [Related]
35. Steatosis and NASH in type 2 diabetes. Hu M; Phan F; Bourron O; Ferré P; Foufelle F Biochimie; 2017 Dec; 143():37-41. PubMed ID: 29097281 [TBL] [Abstract][Full Text] [Related]
38. Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis. Kasumov T; Li L; Li M; Gulshan K; Kirwan JP; Liu X; Previs S; Willard B; Smith JD; McCullough A PLoS One; 2015; 10(5):e0126910. PubMed ID: 25993337 [TBL] [Abstract][Full Text] [Related]
39. Non-alcoholic steatohepatitis in children. Nanda K Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336 [TBL] [Abstract][Full Text] [Related]
40. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]